Lorraine V. Kalia
Krembil Research Institute,
Toronto Western Hospital,
Department of Medicine,
Division of Neurology,
Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic,
Krembil Research Institute, Toronto Western Hospital,
Department of Medicine, Division of Neurology, Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital
University Health Network
Lorraine Kalia received her MD/PhD and neurology residency training at the University of Toronto, Canada. She conducted a postdoctoral research fellowship at Massachusetts General Hospital, USA and a movement disorders fellowship at Toronto Western Hospital, Canada.
Currently, she is an associate professor and clinician-scientist in the Division of Neurology, Department of Medicine at the University of Toronto. She is also a senior scientist at the Krembil Research Institute of the University Health Network. She holds appointments with the University of Toronto’s Tanz Centre for Research in Neurodegenerative Diseases and Department of Laboratory Medicine and Pathobiology.
Her research program focuses on Parkinson’s disease and related movement disorders. She heads a research team focused on elucidating the critical molecular mechanisms responsible for neurodegeneration in Parkinson’s disease and identifying therapeutic agents that can modulate or target these molecular mediators of neurodegeneration. She has received research funding from the Canadian Institutes of Health Research, J. P. Bickell Foundation, Michael J. Fox Foundation for Parkinson's Research, Natural Sciences and Engineering Research Council of Canada, Ontario Brain Institute, Parkinson Canada, Parkinson's UK, and Toronto General & Western Hospital Foundation.
NMDA receptors in clinical neurology: excitatory times ahead.
The Lancet. Neurology Aug, 2008 | Pubmed ID: 18635022
Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5).
PloS one Feb, 2011 | Pubmed ID: 21358815
Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly.
Neurology Mar, 2012 | Pubmed ID: 22411959
Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics Jan, 2014 | Pubmed ID: 24085420
Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.
Proceedings of the National Academy of Sciences of the United States of America Feb, 2014 | Pubmed ID: 24510904
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.
JAMA neurology Jan, 2015 | Pubmed ID: 25401511
α-Synuclein and Lewy pathology in Parkinson's disease.
Current opinion in neurology Aug, 2015 | Pubmed ID: 26110807
Disease-modifying strategies for Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society Sep, 2015 | Pubmed ID: 26208210
Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease.
Molecular therapy. Methods & clinical development , 2016 | Pubmed ID: 26817024
α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.
Trends in neurosciences 11, 2016 | Pubmed ID: 27776749
α-Synuclein and Parkinsonism: Updates and Future Perspectives.
Current neurology and neuroscience reports 04, 2017 | Pubmed ID: 28324300
Animal models of α-synucleinopathy for Parkinson disease drug development.
Nature reviews. Neuroscience Sep, 2017 | Pubmed ID: 28747776
Biomarkers for cognitive dysfunction in Parkinson's disease.
Parkinsonism & related disorders Jan, 2018 | Pubmed ID: 28781202
Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.
Parkinson's disease , 2017 | Pubmed ID: 28913005
Complex genomic rearrangement in SPG11 due to a DNA replication-based mechanism.
Movement disorders : official journal of the Movement Disorder Society 12, 2017 | Pubmed ID: 29082553
Is there a role for MR-guided focused ultrasound in Parkinson's disease?
Movement disorders : official journal of the Movement Disorder Society 04, 2018 | Pubmed ID: 29476631
Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease.
British journal of pharmacology 08, 2018 | Pubmed ID: 29722028
Tremor in Spinocerebellar Ataxia Type 12.
Movement disorders clinical practice Apr, 2014 | Pubmed ID: 30363887
Parkinsonism due to A53E α-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features.
Movement disorders : official journal of the Movement Disorder Society 12, 2018 | Pubmed ID: 30423204
Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.
Parkinsonism & related disorders 02, 2019 | Pubmed ID: 30466800
Deep brain stimulation: potential for neuroprotection.
Annals of clinical and translational neurology 01, 2019 | Pubmed ID: 30656196
The clinical significance of lower limb tremors.
Parkinsonism & related disorders 08, 2019 | Pubmed ID: 31201091
Multiple system atrophy and myoclonus: A morphologic marker in the spinal cord?
Neurology 08, 2019 | Pubmed ID: 31405931
Expert comment: "A case of missing pathology in a patient with LRRK2 Parkinson's disease".
Parkinsonism & related disorders 05, 2020 | Pubmed ID: 31727562
Bcl-2-associated athanogene 5 (BAG5) regulates Parkin-dependent mitophagy and cell death.
Cell death & disease 12, 2019 | Pubmed ID: 31787745
Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein.
Acta neuropathologica communications 02, 2020 | Pubmed ID: 32059750
Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?
Neurology 03, 2020 | Pubmed ID: 32102975
Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease.
Critical reviews in clinical laboratory sciences 08, 2020 | Pubmed ID: 32116096
Deep Brain Stimulation of the Medial Septal Nucleus Induces Expression of a Virally Delivered Reporter Gene in Dentate Gyrus.
Frontiers in neuroscience , 2020 | Pubmed ID: 32477058
LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease?
Frontiers in neuroscience , 2020 | Pubmed ID: 32625052
Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson's disease.
Journal of neurosurgery Aug, 2020 | Pubmed ID: 32764177
Regulation of Parkin-dependent mitophagy by Bcl-2-associated athanogene (BAG) family members.
Neural regeneration research Apr, 2021 | Pubmed ID: 33063725
The eIF2α kinase HRI triggers the autophagic clearance of cytosolic protein aggregates.
The Journal of biological chemistry Nov, 2020 | Pubmed ID: 33168630
C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current neuropharmacology 11, 2020 | Pubmed ID: 33200713
The eIF2α kinase HRI triggers the autophagic clearance of cytosolic protein aggregates.
The Journal of biological chemistry Dec, 2020 | Pubmed ID: 33410405
AN INTELLIGENT DIAGNOSIS: SMART SYNDROME.
The American journal of medicine Jan, 2021 | Pubmed ID: 33444593
Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis
Darren M. O'Hara1,2,
Minesh Kapadia1,2,
Susan Ping1,2,
Suneil K. Kalia1,2,3,
Lorraine V. Kalia1,2,4,5,6
1Krembil Research Institute, Toronto Western Hospital, University Health Network,
2Department of Laboratory Medicine and Pathobiology, University of Toronto,
3Department of Surgery, Division of Neurosurgery, University of Toronto,
4Department of Medicine, Division of Neurology, University of Toronto,
5Department of Medicine, Division of Neurology, Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network,
6Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto
À PROPOS DE JoVE
Copyright © 2024 MyJoVE Corporation. Tous droits réservés.